Factor Structure of the National Alzheimer's Coordinating Centers Uniform Dataset Neuropsychological Battery An Evaluation of Invariance Between and Within Groups Over Time

Joseph and Kathleen Bryan Alzheimer's Disease Research Center, Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC 27705, USA.
Alzheimer disease and associated disorders (Impact Factor: 2.69). 04/2011; 25(2):128-37. DOI: 10.1097/WAD.0b013e3181ffa76d
Source: PubMed

ABSTRACT The neuropsychological battery from the National Alzheimer's Disease Coordinating Center is designed to provide a sensitive assessment of mild cognitive disorders for multicenter investigations. Comprising 8 common neuropsychological tests (12 measures), the battery assesses cognitive domains affected early in the course of Alzheimer disease. We examined the factor structure of the battery across levels of cognition [normal, mild cognitive impairment, dementia] based on Clinical Dementia Rating scores to determine cognitive domains tapped by the battery. Using data pooled from 29 Alzheimer's Disease Centers funded by National Institute on Aging, exploratory factor analysis was used to derive a general model using half of the sample; 4 factors representing memory, attention, executive function, and language were identified. Confirmatory factor analysis was used on the second half of the sample to evaluate invariance between groups and within groups over 1 year. Factorial invariance testing included systematic addition of constraints and comparisons of nested models. The general confirmatory factor analysis model had a good fit. As constraints were added, model fit deteriorated slightly. Comparisons within groups showed stability over 1 year. In a range of cognition from normal to dementia, factor structures and factor loadings will vary little. Further work is needed to determine whether domains become more or less distinct in severely cognitively compromised individuals.

Download full-text


Available from: Jeffrey Browndyke, Jun 18, 2015
  • [Show abstract] [Hide abstract]
    ABSTRACT: To determine whether asymptomatic persons with Alzheimer disease (AD) neuropathologic change differ in the trajectory of their cognitive performance compared to asymptomatic persons without AD neuropathologic change.METHODS: Longitudinal performance on standard neuropsychological tests was examined in participants who died within 2 years of their last cognitive assessment and who were never diagnosed with mild cognitive impairment or dementia (Clinical Dementia Rating global score of 0 at all assessments). Using cognitive and neuropathologic data collected between 2005 and 2013 from the 34 National Institute on Aging-sponsored Alzheimer's Disease Centers, cognitive trajectories were compared for persons with and without evidence of AD neuropathologic change. We evaluated rates of decline in 4 domains (episodic memory, language, attention/working memory, executive function). The significance of the differences (β) in rates of decline was tested using linear regression, adjusting for age, education, sex, and other neuropathologic lesions.RESULTS: Participants who had low to high levels of AD neuropathologic change (n = 131) showed a greater rate of decline on the attention/working memory domain score (β = -0.11; 95% confidence interval = -0.19, -0.02; p = 0.02) when compared to 80 participants who died without evidence of AD neuropathologic change.CONCLUSIONS: Clinically normal individuals who come to autopsy with AD neuropathologic change exhibit subtle evidence of declining cognitive trajectories for attention/working memory.
    Neurology 06/2014; 83(5). DOI:10.1212/WNL.0000000000000650 · 8.30 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Cognitive profiles for pre-clinical Alzheimer disease (AD) can be used to identify groups of individuals at risk for disease and better characterize pre-clinical disease. Profiles or patterns of performance as pre-clinical phenotypes may be more useful than individual test scores or measures of global decline. To evaluate patterns of cognitive performance in cognitively normal individuals to derive latent profiles associated with later onset of disease using a combination of factor analysis and latent profile analysis. The National Alzheimer Coordinating Centers collect data, including a battery of neuropsychological tests, from participants at 29 National Institute on Aging-funded Alzheimer Disease Centers across the United States. Prior factor analyses of this battery demonstrated a four-factor structure comprising memory, attention, language, and executive function. Factor scores from these analyses were used in a latent profile approach to characterize cognition among a group of cognitively normal participants (N = 3,911). Associations between latent profiles and disease outcomes an average of 3 years later were evaluated with multinomial regression models. Similar analyses were used to determine predictors of profile membership. Four groups were identified; each with distinct characteristics and significantly associated with later disease outcomes. Two groups were significantly associated with development of cognitive impairment. In post hoc analyses, both the Trail Making Test Part B, and a contrast score (Delayed Recall - Trails B), significantly predicted group membership and later cognitive impairment. Latent profile analysis is a useful method to evaluate patterns of cognition in large samples for the identification of preclinical AD phenotypes; comparable results, however, can be achieved with very sensitive tests and contrast scores.
    The American journal of geriatric psychiatry: official journal of the American Association for Geriatric Psychiatry 09/2013; 22(11). DOI:10.1016/j.jagp.2013.07.008 · 3.52 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The PGSA (Placebo Group Simulation Approach) aims at avoiding problems of sample representativeness and ethical issues typical of placebo-controlled secondary prevention trials with MCI patients. The PGSA uses mathematical modeling to forecast the distribution of quantified outcomes of MCI patient groups based on their own baseline data established at the outset of clinical trials. These forecasted distributions are then compared with the distribution of actual outcomes observed on candidate treatments, thus substituting for a concomitant placebo group. Here we investigate whether a PGSA algorithm that was developed from the MCI population of ADNI 1*, can reliably simulate the distribution of composite neuropsychological outcomes from a larger, independently selected MCI subject sample. Data available from the National Alzheimer's Coordinating Center (NACC) were used. We included 1523 patients with single or multiple domain amnestic mild cognitive impairment (aMCI) and at least two follow-ups after baseline. In order to strengthen the analysis and to verify whether there was a drift over time in the neuropsychological outcomes, the NACC subject sample was split into 3 subsamples of similar size. The previously described PGSA algorithm for the trajectory of a composite neuropsychological test battery (NTB) score was adapted to the test battery used in NACC. Nine demographic, clinical, biological and neuropsychological candidate predictors were included in a mixed model; this model and its error terms were used to simulate trajectories of the adapted NTB. The distributions of empirically observed and simulated data after 1, 2 and 3 years were very similar, with some over-estimation of decline in all 3 subgroups. The by far most important predictor of the NTB trajectories is the baseline NTB score. Other significant predictors are the MMSE baseline score and the interactions of time with ApoE4 and FAQ (functional abilities). These are essentially the same predictors as determined for the original NTB score. An algorithm comprising a small number of baseline variables, notably cognitive performance at baseline, forecasts the group trajectory of cognitive decline in subsequent years with high accuracy. The current analysis of 3 independent subgroups of aMCI patients from the NACC database supports the validity of the PGSA longitudinal algorithm for a NTB. Use of the PGSA in long-term secondary AD prevention trials deserves consideration.